Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Research Abstract |
The regulatory mechanisms, which could be applicable for the treatment of allergic contact dermatitis, are still largely unknown. To determine roles of B and T lymphocyte attenuator (BTLA) in hapten-induced contact hypersensitivity (CHS), BTLA KO mice and wild-type (WT) mice were subjected to dinitrofluorobenzene (DNFB)-induced CHS. BTLA KO mice showed enhanced CHS as compared to WT mice. To evaluate the therapeutic potential of an agonistic agent for BTLA on CHS, the effects of an agonistic anti-BTLA antibody (6A6) on CHS were examined. In vivo injection of 6A6 suppressed CHS. Taken together, these results suggest that stimulation of BTLA with agonistic agents has therapeutic potential in CHS.
|